Table 1

 Comparison of clinical, laboratory and MRI features between NMO-IgG-positive OSMS and NMO-IgG-negative OSMS patients

NMO-IgG positiveNMO-IgG negativep Value
Total (n = 14)OSMS (n = 12)OSMS (n = 7)
ANA, anti-nuclear antibodies; CMS, conventional form of multiple sclerosis; EDSS, Expanded Disability Status Scale; OB, oligoclonal IgG bands; OSMS, optic–spinal form of multiple sclerosis; p Value, compared between NMO-IgG-positive OSMS and NMO-IgG-negative OSMS using Mann–Whitney U test or Fisher’s exact test; SMS, spinal form of multiple sclerosis; VS, vertebral segments.
Values in bold are significant (p<0.05).
Age, years (SD)47 (15)49 (15)46 (14)0.642
Age at onset, years (SD)36 (13)37 (13)36 (13)0.734
EDSS, median (range)6.0 (2.0–8.0)6.0 (3.5–8.0)6.0 (0–6.5)0.217
Transverse myelitis12 (86%)11 (92%)5 (71%)0.523
Permanent complete blindness7 (50%)7 (58%)0 (0%) 0.017
CSF marked pleocytosis (>50 cells/μl)4 (29%)4 (33%)1 (14%)0.603
OB2 (14%)2 (17%)0 (0%)0.509
Serum ANA8/13 (62%)6/11 (55%)4 (57%)>0.999
MRI
    Long-cord lesions (>3VS)13 (93%)12 (100%)4 (57%) 0.036
    Cerebral lesions6 (43%)4 (33%)5 (71%)0.1698